GO:0060915 mesenchymal cell differentiation involved in lung development: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060915 describes the process by which unspecialized cells acquire the specialized features of lung mesenchymal cells, which form the connective tissue framework of the lung.
• Mesenchymal cell differentiation in the lung is driven by paracrine signals such as fibroblast growth factor 10 (FGF10) and retinoic acid, which pattern the mesenchyme and coordinate branching morphogenesis.
• Dysregulation of mesenchymal differentiation contributes to pulmonary fibrosis, where fibroblasts and myofibroblasts expand and deposit excessive extracellular matrix.
• Endothelial-to-mesenchymal transition (EndoMT) and fibroblast proliferation are key pathological mechanisms in lung fibrosis and are targeted by signaling pathways such as PTPRB and TGF-β-WNT crosstalk.
• SWI/SNF chromatin remodeling complex mutations are linked to thoraco-pulmonary neoplasms, highlighting the role of epigenetic regulators in mesenchymal cell fate.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of genes involved in lung mesenchymal differentiation and disease.
Description
Mesenchymal cell differentiation involved in lung development (GO:0060915) is a biological process in which relatively unspecialized cells acquire the specialized features of mesenchymal cells of the lung. Mesenchymal cells are loosely associated cells that form the connective tissue of the lung and give rise to more mature connective tissue cell types, including fibroblasts, myofibroblasts, and smooth muscle cells. This process is essential for lung branching morphogenesis, alveolarization, and the establishment of the pulmonary vasculature. Disruption of mesenchymal differentiation is implicated in a range of pulmonary pathologies, from fibrosis to congenital malformations and neoplasms. Understanding the molecular players and signaling cascades that govern this process is therefore critical for developmental biology and respiratory medicine. Recent studies have highlighted the roles of FGF10, retinoic acid, TGF-β, WNT, and chromatin remodeling complexes in controlling mesenchymal cell fate decisions during lung development and disease. This article synthesizes the current knowledge on GO:0060915, covering its definition, mechanisms, key genes, disease associations, and research methodologies, with a focus on CRISPR-based approaches for functional interrogation.
mesenchymal cell differentiation involved in lung development At A Glance
| GO ID | GO:0060915 |
|---|---|
| GO term | mesenchymal cell differentiation involved in lung development |
| Ontology | biological_process |
| Synonym | None |
| Major function | Differentiation of unspecialized cells into lung mesenchymal cells that form connective tissue and support lung architecture |
| Related processes | Lung branching morphogenesis, alveolarization, extracellular matrix production, endothelial-to-mesenchymal transition |
| Key signaling pathways | FGF10, retinoic acid, TGF-β, WNT, PTPRB |
| Disease relevance | Pulmonary fibrosis, pulmonary arterial hypertension, thoraco-pulmonary neoplasms |
What Is GO:0060915?
GO:0060915, mesenchymal cell differentiation involved in lung development, is defined as the process in which a relatively unspecialized cell acquires specialized features of a mesenchymal cell of the lung. A mesenchymal cell is a loosely associated cell that is part of the connective tissue in an organism. Mesenchymal cells give rise to more mature connective tissue cell types. This term encompasses the cellular and molecular events that drive the commitment, differentiation, and maturation of mesenchymal progenitors within the developing lung, contributing to the formation of the lung's connective tissue framework, including fibroblasts, myofibroblasts, and smooth muscle cells.
Why Is mesenchymal cell differentiation involved in lung development Important in Cell Biology?
Mesenchymal cell differentiation involved in lung development is fundamental to building a functional respiratory system. Mesenchymal cells provide structural support, produce extracellular matrix, and secrete signaling molecules that instruct epithelial branching and differentiation. Defects in this process can lead to impaired lung development, congenital lung malformations, and increased susceptibility to chronic lung diseases such as pulmonary fibrosis and pulmonary arterial hypertension. Moreover, reactivation of developmental mesenchymal differentiation programs is a hallmark of pathological fibrosis and cancer-associated stroma. Thus, understanding GO:0060915 offers insights into both normal lung biology and disease pathogenesis, and it provides a rationale for targeting mesenchymal cell fate as a therapeutic strategy.
• Essential for lung branching morphogenesis and alveolarization during development.
• Mesenchymal cells give rise to fibroblasts, myofibroblasts, and smooth muscle cells that maintain lung structure.
• Dysregulation contributes to pulmonary fibrosis, characterized by excessive mesenchymal cell proliferation and matrix deposition.
• Endothelial-to-mesenchymal transition (EndoMT) is a key mechanism in fibrosis and is regulated by pathways such as PTPRB.
• SWI/SNF chromatin remodeling complex mutations are associated with thoraco-pulmonary neoplasms, linking epigenetic regulation to mesenchymal differentiation.
• FGF10 signaling is critical for mesenchymal cell differentiation and is implicated in lung disease.
• Retinoic acid signaling influences lung development and mesenchymal differentiation.
• Pulmonary arterial hypertension involves remodeling of vascular cells, including mesenchymal-like cells.
• Understanding this process aids in developing regenerative therapies for lung diseases.
• CRISPR screens can identify novel regulators of mesenchymal differentiation for therapeutic targeting.
What Happens During mesenchymal cell differentiation involved in lung development?
Specification of Mesenchymal Progenitors
In simple terms: Early in lung development, some cells receive signals that tell them to become mesenchymal cells.
During lung development, mesenchymal progenitors arise from the splanchnic mesoderm and possibly from other sources such as endothelial cells through endothelial-to-mesenchymal transition (EndoMT). Signaling molecules such as FGF10, secreted by the mesenchyme, act in a paracrine manner to regulate progenitor proliferation and differentiation. Retinoic acid signaling also plays a role in patterning the mesenchyme and promoting differentiation. These early signals establish a pool of mesenchymal progenitors that will give rise to various connective tissue cell types.
Proliferation and Migration of Mesenchymal Cells
In simple terms: Mesenchymal cells multiply and move to the right places to build the lung structure.
Once specified, mesenchymal cells proliferate and migrate to form the scaffolding of the developing lung. FGF10 signaling promotes mesenchymal proliferation and is essential for branching morphogenesis. The extracellular matrix (ECM) produced by these cells provides structural support and biochemical cues that guide migration and differentiation. Dysregulated proliferation and migration of mesenchymal cells are features of pulmonary fibrosis, where fibroblasts and myofibroblasts accumulate and deposit excessive ECM.
Differentiation into Mature Mesenchymal Cell Types
In simple terms: Mesenchymal cells become specialized cell types like fibroblasts and smooth muscle cells.
Mesenchymal progenitors differentiate into mature connective tissue cell types, including fibroblasts, myofibroblasts, and smooth muscle cells. This differentiation is controlled by a network of transcription factors and signaling pathways, including TGF-β, WNT, and FGF. For example, TGF-β signaling promotes myofibroblast differentiation, a process that is critical for wound healing but also drives fibrosis when dysregulated. WNT signaling interacts with TGF-β to regulate mesenchymal cell fate. The SWI/SNF chromatin remodeling complex also plays a role in regulating gene expression programs during mesenchymal differentiation.
Interaction with Epithelial and Endothelial Cells
In simple terms: Mesenchymal cells talk to other lung cells to coordinate lung development.
Mesenchymal cells interact closely with epithelial and endothelial cells to coordinate lung development. Epithelial-derived signals such as SHH and WNT regulate mesenchymal differentiation, while mesenchymal-derived FGF10 signals back to the epithelium to promote branching. Endothelial cells can undergo EndoMT to contribute to the mesenchymal pool, a process that is implicated in pulmonary fibrosis and pulmonary arterial hypertension. This crosstalk is essential for proper lung morphogenesis and homeostasis.
Extracellular Matrix Remodeling
In simple terms: Mesenchymal cells produce and remodel the matrix that supports lung tissue.
Mesenchymal cells synthesize and remodel the extracellular matrix (ECM), which provides structural support and regulates cell behavior. ECM remodeling is dynamic during development but becomes pathological in fibrosis, where excessive deposition of collagen and other matrix components leads to tissue scarring. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are key regulators of ECM turnover, and their imbalance contributes to fibrotic diseases.
Key Genes Involved in GO:0060915 mesenchymal cell differentiation involved in lung development
The following genes and proteins are key players in mesenchymal cell differentiation involved in lung development and its associated pathologies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGF10 | Mesenchymal growth factor that promotes proliferation and differentiation | Critical for lung branching morphogenesis; knockout leads to lung agenesis |
| FGFR2 | Receptor for FGF10; mediates signaling in mesenchymal cells | Mutations linked to lung developmental disorders |
| TGFB1 | Cytokine that induces myofibroblast differentiation and ECM production | Central to pulmonary fibrosis pathogenesis |
| WNT5A | Regulates mesenchymal cell proliferation and differentiation | Involved in TGF-β-WNT crosstalk in fibrosis |
| PTPRB | Protein tyrosine phosphatase that regulates endothelial-to-mesenchymal transition | Target of Forsythoside A in pulmonary fibrosis |
| SMAD2/3 | Transcription factors downstream of TGF-β signaling | Mediate pro-fibrotic gene expression |
| ACTA2 | Smooth muscle actin; marker of myofibroblasts | Increased in fibrosis and smooth muscle differentiation |
| COL1A1 | Type I collagen; major ECM component | Overexpressed in fibrosis |
| FN1 | Fibronectin; ECM glycoprotein | Promotes mesenchymal cell adhesion and migration |
| VIM | Vimentin; mesenchymal intermediate filament | Marker of mesenchymal cells and EndoMT |
| CDH5 | VE-cadherin; endothelial marker lost during EndoMT | Used to assess endothelial-to-mesenchymal transition |
| SMARCB1 | SWI/SNF complex subunit | Mutations in SWI/SNF-deficient thoraco-pulmonary neoplasms |
| SMARCA4 | SWI/SNF ATPase subunit | Altered in lung cancers and sarcomas |
| RARB | Retinoic acid receptor beta | Mediates retinoic acid effects on lung development |
| ALDH1A2 | Retinaldehyde dehydrogenase; synthesizes retinoic acid | Regulates retinoic acid availability in lung mesenchyme |
| SHH | Sonic hedgehog; epithelial signal to mesenchyme | Regulates mesenchymal proliferation and differentiation |
| GLI1 | Transcription factor downstream of SHH | Mediates hedgehog signaling in mesenchyme |
| PDGFRA | Receptor for PDGF; promotes mesenchymal proliferation | Involved in lung fibroblast activation |
How Is mesenchymal cell differentiation involved in lung development Regulated?
The process of mesenchymal cell differentiation involved in lung development is regulated by a complex network of signaling pathways and transcription factors. Key regulators include FGF10, which acts through FGFR2 to promote mesenchymal proliferation and differentiation. Retinoic acid signaling, mediated by RARs and RXRs, influences mesenchymal cell fate and lung branching. TGF-β signaling, via SMAD2/3, induces myofibroblast differentiation and ECM production, and its dysregulation leads to fibrosis. WNT signaling interacts with TGF-β to modulate mesenchymal cell behavior. The SWI/SNF chromatin remodeling complex regulates gene expression programs during differentiation, and its subunits are mutated in thoraco-pulmonary neoplasms. Additionally, PTPRB signaling regulates endothelial-to-mesenchymal transition, a source of mesenchymal cells in disease. These pathways are tightly controlled spatially and temporally to ensure proper lung development, and their perturbation contributes to disease.
mesenchymal cell differentiation involved in lung development and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB1 | Pulmonary fibrosis; drives myofibroblast differentiation | Bleomycin-induced lung fibrosis in mice; TGF-β1 overexpression |
| PTPRB | EndoMT in pulmonary fibrosis; target of Forsythoside A | Endothelial cell-specific knockout or overexpression; bleomycin model |
| SMARCB1 | SWI/SNF-deficient thoraco-pulmonary neoplasms | Conditional knockout in lung mesenchyme; xenograft models |
| FGF10 | Lung developmental disorders; branching morphogenesis | Fgf10 knockout mice; lung explant cultures |
| RARB | Retinoic acid signaling in lung development | Rarb knockout mice; retinoic acid treatment in lung explants |
Pulmonary Fibrosis
Pulmonary fibrosis is a chronic, progressive lung disease characterized by excessive deposition of extracellular matrix and destruction of lung architecture. Dysregulated mesenchymal cell differentiation, particularly the expansion of myofibroblasts, is a central feature. TGF-β signaling is a major driver of fibrosis, promoting myofibroblast differentiation and collagen production. Endothelial-to-mesenchymal transition (EndoMT) also contributes to the mesenchymal cell pool in fibrotic lungs, and inhibition of EndoMT by compounds such as Forsythoside A via PTPRB signaling reduces fibrosis in experimental models. Bleomycin-induced lung fibrosis is a widely used animal model that recapitulates key features of human fibrosis, including mesenchymal cell activation.
Thoraco-Pulmonary Neoplasms
SWI/SNF-deficient thoraco-pulmonary neoplasms are a group of rare tumors that arise in the thorax and lungs. Mutations in SWI/SNF complex subunits, such as SMARCB1 and SMARCA4, are characteristic. These tumors often show mesenchymal-like features, suggesting a link between chromatin remodeling and mesenchymal differentiation programs. Understanding how SWI/SNF mutations affect mesenchymal cell differentiation may provide insights into tumorigenesis and potential therapeutic targets.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a vascular disease characterized by remodeling of pulmonary arteries, leading to increased vascular resistance and right heart failure. Recent studies have identified disease-specific vascular cell populations, including mesenchymal-like cells, that contribute to obliterative arterial remodeling. EndoMT may contribute to the accumulation of mesenchymal-like cells in the vessel wall. Targeting pathways that regulate mesenchymal differentiation could offer new therapeutic approaches for PAH.
Endometriosis-Associated Fibrosis
Although primarily a gynecological disorder, endometriosis is characterized by fibrosis and the presence of mesenchymal-like cells. A systematic review highlighted the role of fibrosis in endometriosis, with similarities to pulmonary fibrosis in terms of mesenchymal cell activation and ECM deposition. While the lung is not the primary site, the mechanisms of mesenchymal differentiation and fibrosis share common pathways, such as TGF-β signaling.
From mesenchymal cell differentiation involved in lung development-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X drive mesenchymal differentiation? | Knockout of gene X in mesenchymal progenitors (e.g., Fgf10-Cre; X fl/fl) |
| Does a point mutation in gene Y alter mesenchymal cell fate? | Point-mutation knock-in mice (e.g., Smarca4 conditional mutation) |
| Can overexpression of gene Z promote myofibroblast differentiation? | Overexpression of gene Z in lung fibroblasts or mesenchymal cells |
| What is the role of gene W in EndoMT? | Endothelial-specific knockout or overexpression of gene W; lineage tracing |
| How does a tagged version of protein V localize in mesenchymal cells? | Tagged knock-in (e.g., GFP or HA tag) for imaging and proteomics |
| Which genes regulate mesenchymal differentiation in a high-throughput manner? | CRISPR library screening in primary lung mesenchymal cells or organoids |
How to Study the mesenchymal cell differentiation involved in lung development Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lineage tracing | Fate of mesenchymal progenitors | Tracking EndoMT contribution to fibrosis |
| scRNA-seq | Transcriptomic heterogeneity | Identifying mesenchymal subpopulations in lung |
| CRISPR screen | Genes required for differentiation | Discovery of novel regulators |
| Co-IP / PLA | Protein-protein interactions | SMAD-chromatin remodeler complexes |
| Phospho-proteomics | Signaling pathway activation | TGF-β and FGF signaling dynamics |
| Immunofluorescence | Protein localization and marker expression | Detecting ACTA2, VIM, CDH5 in tissues |
| Organoid culture | Self-organization and differentiation | Modeling lung mesenchymal-epithelial interactions |
| Bleomycin model | Fibrosis development | Testing anti-fibrotic drugs |
Lineage Tracing and Genetic Fate Mapping
Lineage tracing using Cre-loxP systems allows researchers to follow the fate of mesenchymal progenitors during lung development and in disease models. For example, Fgf10-Cre or Twist2-Cre can label mesenchymal cells and their descendants. This approach has been used to demonstrate the contribution of EndoMT to the mesenchymal pool in pulmonary fibrosis. Combining lineage tracing with single-cell RNA sequencing provides a powerful way to map differentiation trajectories.
Single-Cell RNA Sequencing (scRNA-seq)
scRNA-seq enables the transcriptomic profiling of individual cells, revealing heterogeneity among mesenchymal cells and identifying novel subpopulations and differentiation trajectories. This method has been used to map disease-specific vascular cell populations in pulmonary arterial hypertension, including mesenchymal-like cells. In lung development, scRNA-seq has uncovered distinct mesenchymal subtypes and their gene expression programs.
CRISPR Screens and Functional Genomics
CRISPR-based loss-of-function screens allow systematic identification of genes required for mesenchymal cell differentiation. Pooled sgRNA libraries can be introduced into primary lung mesenchymal cells or organoids, followed by selection for differentiation markers and next-generation sequencing to identify enriched or depleted sgRNAs. This approach can uncover novel regulators and potential therapeutic targets.
Protein-Protein Interaction and Signaling Assays
Co-immunoprecipitation, proximity ligation assays, and phospho-proteomics can dissect signaling pathways involved in mesenchymal differentiation. For example, TGF-β-induced SMAD2/3 phosphorylation can be measured by Western blot, and interactions between SMADs and chromatin remodelers can be assessed by co-IP. These methods help define the molecular mechanisms downstream of key receptors.
How CRISPR Can Be Used to Study GO:0060915 mesenchymal cell differentiation involved in lung development
Knockout
CRISPR knockout (KO) is used to completely ablate a gene of interest to study its role in mesenchymal cell differentiation. For example, knocking out Fgf10 in mice results in lung agenesis, demonstrating its essential role. In vitro, KO of TGFB1 or its receptor in lung fibroblasts can prevent myofibroblast differentiation. KO models are invaluable for establishing causality and identifying pathways that are necessary for the process.
Point Mutation
Point mutations can be introduced via CRISPR to model specific amino acid changes that affect protein function, such as kinase-dead mutants or phosphorylation site mutants. For instance, mutating key residues in SMAD2/3 can disrupt TGF-β signaling and block myofibroblast differentiation. Point mutations in SMARCA4 found in thoraco-pulmonary neoplasms can be knocked into cell lines to study their effects on chromatin remodeling and mesenchymal differentiation.
Knock-in
Knock-in of reporter genes (e.g., GFP, luciferase) or tags (e.g., HA, FLAG) allows visualization and purification of specific cell populations or proteins. For example, knocking in GFP under the Acta2 promoter enables sorting of myofibroblasts. Tagged knock-in of FGF10 can facilitate studies of its secretion and receptor binding. Knock-in of disease-associated mutations, such as those in SMARCB1, can create isogenic models for drug testing.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression constructs can drive ectopic expression of a gene to test sufficiency. Overexpressing TGFB1 in lung mesenchymal cells induces myofibroblast differentiation and fibrosis in vivo. Overexpression of FGF10 can promote mesenchymal proliferation and branching in lung explants. These models help determine whether a gene is sufficient to drive the differentiation process.
How EDITGENE Supports mesenchymal cell differentiation involved in lung development Research
Researchers studying mesenchymal cell differentiation involved in lung development-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. This requires precise genetic manipulation in relevant cell types and model systems. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies, from knockout to knock-in and overexpression, as well as high-throughput library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for mesenchymal cell differentiation involved in lung development research.
Frequently Asked Questions About mesenchymal cell differentiation involved in lung development
What is GO:0060915?
GO:0060915 is the Gene Ontology term for mesenchymal cell differentiation involved in lung development, the process by which unspecialized cells acquire the specialized features of lung mesenchymal cells.
What genes are involved in mesenchymal cell differentiation involved in lung development?
Key genes include FGF10, FGFR2, TGFB1, WNT5A, PTPRB, SMAD2/3, ACTA2, COL1A1, SMARCB1, SMARCA4, RARB, and SHH, among others.
How is mesenchymal cell differentiation involved in lung development regulated?
It is regulated by signaling pathways such as FGF10, retinoic acid, TGF-β, WNT, and chromatin remodeling complexes, which control gene expression programs.
What diseases are associated with defects in mesenchymal cell differentiation in the lung?
Pulmonary fibrosis, thoraco-pulmonary neoplasms, pulmonary arterial hypertension, and developmental lung disorders are associated with dysregulation of this process.
What is the role of FGF10 in lung mesenchymal differentiation?
FGF10 is a mesenchymal growth factor that promotes proliferation and differentiation of mesenchymal cells and is essential for lung branching morphogenesis.
How does TGF-β signaling affect lung mesenchymal cells?
TGF-β signaling induces myofibroblast differentiation and extracellular matrix production, and its dysregulation contributes to pulmonary fibrosis.
What is endothelial-to-mesenchymal transition (EndoMT) in the lung?
EndoMT is a process where endothelial cells acquire mesenchymal features, contributing to the mesenchymal cell pool in fibrosis and pulmonary hypertension.
What research methods are used to study mesenchymal cell differentiation in the lung?
Methods include lineage tracing, single-cell RNA sequencing, CRISPR screens, protein interaction assays, and animal models such as bleomycin-induced fibrosis.
How can CRISPR be used to study genes involved in lung mesenchymal differentiation?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of gene function in mesenchymal cells and lung organoids.
What are the therapeutic implications of targeting mesenchymal differentiation in lung disease?
Inhibiting pathways that drive mesenchymal differentiation, such as TGF-β or PTPRB, may reduce fibrosis and vascular remodeling, offering potential treatments for pulmonary fibrosis and pulmonary arterial hypertension.
Conclusion
GO:0060915, mesenchymal cell differentiation involved in lung development, is a critical biological process that underpins lung morphogenesis and homeostasis. Its dysregulation is central to several pulmonary diseases, including fibrosis, neoplasms, and pulmonary hypertension. Research using CRISPR-based models and advanced omics technologies continues to unravel the molecular mechanisms and identify potential therapeutic targets. EDITGENE provides comprehensive services to support these investigations, from gene knockout to high-throughput screening, empowering researchers to translate discoveries into clinical advances.
References
- 1. Vissers G et al.. 2024. The role of fibrosis in endometriosis: a systematic review.. Hum Reprod Update 30(6):706-750 PMID: 39067455
- 2. Della Latta V et al.. 2015. Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions.. Pharmacol Res 97:122-30 PMID: 25959210
- 3. Kadota T et al.. 2021. Human bronchial epithelial cell-derived extracellular vesicle therapy for pulmonary fibrosis via inhibition of TGF-β-WNT crosstalk.. J Extracell Vesicles 10(10):e12124 PMID: 34377373
- 4. Sesboue C et al.. 2021. SWI/SNF-deficient thoraco-pulmonary neoplasms.. Semin Diagn Pathol 38(3):183-194 PMID: 33451916
- 5. Zhang Q et al.. 2024. Forsythoside A regulates pulmonary fibrosis by inhibiting endothelial-to-mesenchymal transition and lung fibroblast proliferation via the PTPRB signaling.. Phytomedicine 130:155715 PMID: 38788399
- 6. Chytil F. 1996. Retinoids in lung development.. FASEB J 10(9):986-92 PMID: 8801181
- 7. Wu J et al.. 2018. Role of Fibroblast Growth Factor 10 in Mesenchymal Cell Differentiation During Lung Development and Disease.. Front Genet 9:545 PMID: 30487814
- 8. Cober ND et al.. 2025. Mapping disease-specific vascular cell populations responsible for obliterative arterial remodelling during the development of pulmonary arterial hypertension.. Cardiovasc Res 121(13):2095-2112 PMID: 40875786
